Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) CEO Martin A. Lehr acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were bought at an average price of $0.70 per share, with a total value of $70,000.00. Following the transaction, the chief executive officer now owns 920,190 shares in the company, valued at $644,133. This represents a 12.19% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Context Therapeutics Stock Performance
Shares of NASDAQ:CNTX traded down $0.02 during trading on Friday, reaching $0.63. 170,618 shares of the stock were exchanged, compared to its average volume of 302,288. Context Therapeutics Inc. has a 12-month low of $0.49 and a 12-month high of $2.75. The firm has a market cap of $56.46 million, a price-to-earnings ratio of -0.69 and a beta of 1.86. The firm's 50-day moving average price is $0.75 and its 200 day moving average price is $0.91.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05). As a group, equities research analysts forecast that Context Therapeutics Inc. will post -0.51 EPS for the current year.
Hedge Funds Weigh In On Context Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Context Therapeutics in the 4th quarter worth approximately $29,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $31,000. Shay Capital LLC acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $52,000. Landscape Capital Management L.L.C. acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $94,000. Finally, Walleye Capital LLC raised its position in shares of Context Therapeutics by 51.7% in the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after purchasing an additional 56,651 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have commented on CNTX. William Blair restated an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Thursday, May 8th. Finally, HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Context Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $6.00.
Read Our Latest Stock Report on CNTX
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Further Reading
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
